Roots Analysis is pleased to announce the publication of its recent study, titled, “Neoantigen Targeted ... Read more

Presently, in silico tools / approaches are available for the identification, selection and optimization of pharmacological leads. in fact, the predictive power of such solutions has been demonstrated to enable researchers to bypass the traditional experimental screening of billions of molecules ... Read more

Roots Analysis is pleased to announce the publication of its recent study, titled, “In Silico / Computer-Aided Drug Discovery Services Market: Focus on ... Read more

Over the years, extensive R&D efforts have enabled microbiome-based therapy / diagnostic developers to make significant strides, in terms of progressing proprietary product candidates into the clinic

Roots Analysis ... Read more

Development initiatives of HPAPIs and cytotoxic drugs are generally very demanding, both in terms of experience and capital investment. Most companies generally lack the necessary resources to meet the aforementioned requirements and are unable to set up dedicated HPAPI and cytotoxic drug ... Read more

Manufacturing highly potent drug products is technically and financially demanding; as a result, drug manufacturers are becoming increasingly reliant on contract service providers

Roots Analysis is pleased to announce the ... Read more

According to experts in this field, fragment-based drug discovery solutions have facilitated the identification of viable pharmacological leads against otherwise hard to target biomolecules. In fact, many service provider companies are offering fragment libraries and support to the medical ... Read more

Screening small molecule fragments has made it possible to identify pharmacological leads against otherwise hard to target hotspots on biomolecules, such as allosteric sites, rendering this approach a valuable alternative method of drug discovery

... Read more